The survival proportion in Figure 5C clearly demonstrates that the combined HAGE/WT1 ImmunoBody® vaccines were able to significantly delay the aggressive growth of B16 melanoma cells and increases the overall survival in the prophylactic setting in comparison to the control at **P-value<0.01. Here, WT1 is linked to melanoma.